Welcome!

.NET Authors: Pat Romanski, Bob Gourley, Michael Jannery, Yakov Fain, Srinivasan Sundara Rajan

News Feed Item

Solta Medical Reports Fourth Quarter and Full Year 2012 Results

Fourth Quarter Revenue Up 20% from Prior Year; 2012 Revenue up 25%

HAYWARD, Calif., Feb. 19, 2013 /PRNewswire/ -- Solta Medical, Inc. (NASDAQ: SLTM), a global leader in the medical aesthetics market, today announced results for the fourth quarter ended December 31, 2012. Revenue for the fourth quarter was $39.8 million, an increase of $6.6 million, or 20%, as compared to the fourth quarter of 2011. Revenue from Liposonix, the Company's non-invasive fat reduction system, was $7.6 million, which was generated from shipments of 90 systems and associated consumables. For the full year 2012, revenue of $144.5 million grew year-over-year by $28.6 million or 25%.

"The fourth quarter provided a strong ending to a productive year for Solta," said Stephen J. Fanning, Chairman, President and CEO of Solta.  "We completed the integration of the Liposonix acquisition ahead of plan and the first year of the Liposonix commercial launch exceeded our expectations. During the year, we shipped approximately 360 Liposonix systems, generating $32 million in revenue. We also generated double digit revenue growth from our Clear + Brilliant brand. We continued to execute well, extending our broad product portfolio through a large distribution network and focusing on recurring revenue.  The increase in the gross margin, and our delivery of positive non-GAAP EBITDA in the fourth quarter and in every quarter over the past three years demonstrate the leverage in our business model. We also generated cash from operations of $1.4 million in the fourth quarter and $4.4 million for the full year ended 2012, and finished the year with $38 million in cash on the balance sheet."

Fourth Quarter Financial Highlights

Total product revenue from treatment tips and consumables for the quarter was $18.8 million, a year-over-year increase of $2.9 million or 18%, and represented 47% of total revenue.  Revenue from North America and international markets rose year-over-year by 17% and 23%, respectively.

GAAP net loss for the quarter was $45,000 as compared to GAAP net income of $1.0 million reported for the fourth quarter of 2011. The prior year net income included the one-time release of a valuation allowance of $6.4 million to offset deferred tax liabilities generated from acquiring Liposonix. Non-GAAP net income for the quarter was $2.3 million, or $0.03 per diluted share, as compared to a non-GAAP net loss of $23,000 for same period last year. Non-GAAP adjusted EBITDA for the quarter was $4.0 million compared to $1.3 million for the same period last year.

The Company's GAAP results for the quarter include $1.8 million of amortization and other acquisition related charges, $1.0 million of non-cash stock based compensation charges, and a $0.5 million credit adjustment for the fair value reassessment of the expected earn out payments associated with the acquisition of Liposonix. The Company provides non-GAAP financial measures that exclude these charges and adjustments. A reconciliation of GAAP to non-GAAP results is provided in the tables included in this release.

Full Year 2012 Financial Results

Total product revenue from treatment tips and consumables for the year was $70.6 million, a year-over-year increase of $7.3 million or 11%, and represented 49% of total revenue.  Revenue from North America and international markets rose year-over-year by 34% and 17%, respectively.

The GAAP net loss for the year was $38.0 million, or a loss of $0.59 per share, as compared to a net loss of $1.3 million, or a loss of $0.02 per share reported for the full year 2011. Non-GAAP net income for the full year was $6.1 million, or $0.09 per diluted share as compared to non-GAAP net income of $3.6 million, or $0.06 per diluted share reported for the full year 2011.  Non-GAAP EBITDA for the full year 2012 was $12.0 million as compared to $7.5 million in the prior year.

Solta Medical's GAAP results for the full year 2012 include charges for the fair value reassessment of the expected earn out payments associated with the acquisition of Liposonix of $32.1 million, non-cash amortization and other acquisition related charges of $7.5 million, and non-cash stock based compensation charges of $4.6 million. The Company provides additional non-GAAP financial measures that exclude these charges and expenses. A reconciliation of GAAP to non-GAAP results is provided in the tables included in this release.

"With the pending acquisition of Sound Surgical, we anticipate continued growth, execution, and operating leverage in 2013. We expect to close the acquisition of Sound Surgical Technologies in the coming weeks and to expeditiously implement our integration plans. With the addition of Sound Surgical's VASER® product line, we look forward to offering our customers an expanded portfolio of innovative, safe, and effective body contouring solutions," said Mr. Fanning.

Financial Outlook for 2013

The company provided its preliminary financial outlook for 2013 which includes the pending acquisition of Sound Surgical Technologies as follows:

  • Revenue for the full year 2013 is expected to grow by 26% to 32% and be in the range of $182 million to $191 million, compared to full year 2012 revenue of $144.5 million.
  • Non-GAAP gross margin is expected to be in the range of 65% to 68% for the full year 2013.  Non-GAAP gross margin excludes non-cash amortization charges, non-cash stock based compensation charges, severance costs, and acquisition related adjustments. Non-GAAP gross margin for the full year 2012 was 66%.
  • Non-GAAP operating income is expected to be in the range of $13 million to $16 million for the full year 2013. Non-GAAP operating income for the first six months of 2013 is expected to be in the range $3 million to $4 million as the Company integrates its acquisition of Sound Surgical Technologies. Non-GAAP operating income excludes non-cash amortization charges, non-cash stock based compensation charges, severance costs, and acquisition related adjustments. Non-GAAP operating income for the full year 2012 was $8.4 million.

Non-GAAP Presentation

To supplement the condensed consolidated financial information presented on a GAAP basis, management has provided non-GAAP gross margin, non-GAAP operating income (loss), non-GAAP adjusted EBITDA, non-GAAP net income (loss) and non-GAAP earnings (loss) per share measures that exclude the impact of acquisition related adjustments, severance costs, acquisition related costs, and stock-based compensation expenses.  The Company believes that these non-GAAP financial measures provide investors with insight into what is used by management to conduct a more meaningful and consistent comparison of the Company's ongoing operating results and trends, compared with historical results.  This presentation is also consistent with the measures management uses to measure the performance of ongoing operating results against prior periods and against our internally developed targets.  There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies.  These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures.  Investors and potential investors should consider non-GAAP financial measures only in conjunction with the Company's consolidated financial statements prepared in accordance with GAAP and the reconciliation of non-GAAP financial measures attached to this release.

Conference Call Information

The Company will host a conference call and webcast today, Tuesday, February 19, 2013, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific) to discuss the financial results and current corporate developments. The dial-in number for the conference call is 877-941-0844 for domestic participants and 480-629-9835 for international participants.

To access the live webcast of the call, go to Solta Medical's website at www.solta.com and click on Investor Relations. An archived webcast will also be available at www.solta.com.

About Solta Medical, Inc.

Solta Medical, Inc. is a global leader in the medical aesthetics market providing innovative, safe, and effective solutions for patients that enhance and expand the practice of medical aesthetics for physicians. The company offers six aesthetic energy devices to address a range of issues, including skin resurfacing and rejuvenation with Fraxel® and Clear + Brilliant(TM), body contouring and skin tightening with Liposonix® and Thermage® and acne reduction with Isolaz® and CLARO(TM). As the innovator and leader in fractional laser technology, Fraxel delivers minimally invasive clinical solutions to resurface aging and sun damaged skin. Using similar fractional laser technology, Clear + Brilliant is a unique, cost-effective treatment to prevent and improve the early signs of photoaging. For body contouring, Liposonix is a non-surgical treatment to reduce waist circumference with advanced high-intensity focused ultrasound (HIFU) technology to permanently destroy targeted fat beneath the skin. Thermage is an innovative, non-invasive radiofrequency procedure for tightening and contouring skin. Isolaz was the first laser or light based system indicated for the treatment of inflammatory acne, comedonal acne, pustular acne, and mild-to-moderate inflammatory acne. CLARO is a personal care acne system that is the first FDA cleared over-the-counter IPL device that uses a powerful combination of both heat and light to clear skin quickly and naturally. More than two million procedures have been performed with Solta Medical's portfolio of products around the world. For more information about Solta Medical, call 1-877-782-2286 or log on to www.Solta.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding the ability to improve operating leverage, the close of the Sound Surgical acquisition, and the financial outlook for 2013. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause Solta Medical's actual results to differ materially from the statements contained herein. Factors that might cause such a difference include the risk that physician adoption of the Company's systems does not grow, the risk that customers do not continue to purchase treatment tips, the possibility that the market for the sale of new products does not develop as expected, and the risks relating to Solta Medical's ability to achieve its stated financial goals as a result of, among other things, economic conditions and consumer and physician confidence causing changes in consumer and physician spending habits that affect demand for the Company's products and treatments. Further information on potential risk factors that could affect Solta Medical's business and its financial results are detailed in its Form 10-K for the year ended December 31, 2011, and other reports as filed from time to time with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, especially guidance on future financial performance, which speaks only as of the date they are made. Solta Medical undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

Web Site: http://www.Solta.com

 

 

Solta Medical, Inc. 

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS 

(in thousands of dollars, except share and per share data)

(unaudited)






Three Months Ended


Twelve Months Ended


December 31,


December 31,


2012


2011


2012


2011









Net revenue 

$39,801


$33,168


$144,545


$115,984

Cost of revenue 

15,630


14,064


55,368


42,364









Gross margin 

24,171


19,104


89,177


73,620









Operating expenses:








Sales and marketing 

13,643


12,244


53,665


46,761

Research and development 

5,382


5,246


20,549


16,124

General and administrative 

4,805


5,440


18,637


17,443

Remeasurement of contingent consideration liability

(500)


1,200


32,100


322









Total operating expenses 

23,330


24,130


124,951


80,650









Income (loss) from operations 

841


(5,026)


(35,774)


(7,030)

Interest income

6


7


14


59

Interest expense

(936)


(119)


(2,014)


(209)

Other income and expense, net

77


(121)


(24)


(309)









Loss before income taxes 

(12)


(5,259)


(37,798)


(7,489)

Income tax provision (benefit) 

33


(6,306)


210


(6,160)









Net income (loss)

($45)


$1,047


($38,008)


($1,329)









Net income (loss) per share:








Basic

($0.00)


$0.02


($0.59)


($0.02)

Diluted

($0.00)


$0.02


($0.59)


($0.02)









Weighted average shares outstanding used in calculating net income (loss) per share:















Basic

68,636,725


60,959,189


64,437,427


60,573,428

Diluted

68,636,725


62,044,555


64,437,427


60,573,428

















Solta Medical, Inc.

NON-GAAP RECONCILIATION OF GROSS MARGIN, OPERATING INCOME (LOSS), EBITDA, NET INCOME (LOSS) AND NET INCOME (LOSS) PER SHARE

  (in thousands, except share and per share data)

(unaudited)










Three Months Ended


Twelve Months Ended


December 31,


December 31,


2012


2011


2012


2011









GAAP Gross margin

$24,171


$19,104


$89,177


$73,620

GAAP gross margin as % of sales

61%


58%


62%


63%

Non-GAAP adjustments to gross margin:








GAAP Gross margin

$24,171


$19,104


$89,177


$73,620

Amortization and other non-cash acquisition related charges

1,375


1,418


5,782


3,951

Stock-based compensation

133


173


499


442

Non-GAAP gross margin

$25,679


$20,695


$95,458


$78,013

Non-GAAP gross margin as % of sales

65%


62%


66%


67%









GAAP income (loss) from operations

$841


($5,026)


($35,774)


($7,030)

Non-GAAP adjustments to net income (loss) from operations:








Amortization and other non-cash acquisition related charges

1,730


1,745


7,205


5,075

Remeasurement of contingent consideration liability

(500)


1,200


32,100


322

Acquisition-related expenses

101


1,120


268


2,355

Severance expenses

-


260


1


260

Stock-based compensation

1,010


1,016


4,563


3,297

Non-GAAP income from operations

$3,182


$315


$8,363


$4,279

Depreciation expenses

847


991


3,665


3,269

Non-GAAP Adjusted EBITDA

$4,029


$1,306


$12,028


$7,548









GAAP net income (loss)             

($45)


$1,047


($38,008)


($1,329)

Non-GAAP adjustments to net income (loss):








Amortization and other non-cash acquisition related charges

1,730


1,745


7,205


5,075

Remeasurement of contingent consideration liability

(500)


1,200


32,100


322

Acquisition-related expenses

101


1,120


268


2,355

Severance expenses

-


260


1


260

Stock-based compensation

1,010


1,016


4,563


3,297

Acquisition-related income tax benefit

-


(6,411)


-


(6,411)

Non-GAAP net income (loss) 

$2,296


($23)


$6,129


$3,569









GAAP basic net income (loss) per share

($0.00)


$0.02


($0.59)


($0.02)

Non-GAAP adjustments to basic income (loss) per share:








Amortization and other non-cash acquisition related charges

$0.03


$0.03


$0.11


$0.08

Remeasurement of contingent consideration liability

($0.01)


$0.02


$0.51


$0.01

Acquisition-related expenses

$0.00


$0.02


$0.00


$0.05

Severance expenses

$0.00


$0.00


$0.00


$0.00

Stock-based compensation

$0.01


$0.02


$0.07


$0.05

Acquisition-related income tax benefit

$0.00


($0.11)


$0.00


($0.11)

Non-GAAP basic net income (loss) per share

$0.03


($0.00)


$0.10


$0.06









Non-GAAP diluted net income (loss) per share

$0.03


($0.00)


$0.09


$0.06









GAAP weighted average shares outstanding used in calculating basic net income (loss) per share

68,636,725


60,959,189


64,437,427


60,573,428









GAAP weighted average shares outstanding used in calculating diluted net income (loss) per share

68,636,725


62,044,555


64,437,427


60,573,428

Adjustments for dilutive potential common stock

4,778,891


1,806,441


5,170,881


3,555,057

Weighted average shares outstanding used in calculating non-GAAP diluted net income (loss) per share

73,415,616


63,850,996


69,608,308


64,128,485

 

Solta Medical, Inc. 

CONDENSED CONSOLIDATED BALANCE SHEETS 

(in thousands of dollars, except share and per share data)

(unaudited)






December 31,


December 31,


2012


2011





ASSETS

Current assets:




Cash and cash equivalents 

$38,097


$17,417

Accounts receivable

20,570


13,282

Inventories

16,611


16,524

Prepaid expenses and other current assets 

8,476


8,626





Total current assets 

83,754


55,849

Property and equipment, net 

6,401


6,818

Purchased intangible assets, net

42,428


49,352

Goodwill

96,620


96,620

Other assets 

520


659





Total assets 

$229,723


$209,298





LIABILITIES AND STOCKHOLDERS' EQUITY

Liabilities:




Accounts payable 

$7,283


$5,767

Accrued liabilities 

17,343


16,126

Current portion of contingent consideration liability

21,400


Current portion of deferred revenue 

3,985


4,521

Short-term borrowings

8,345


7,441

Customer deposits 

637


610





Total current liabilities 

58,993


34,465

Deferred revenue, net of current portion 

683


824

Term loan, net of current portion

18,063


16,959

Non-current tax liabilities

2,478


2,975

Contingent consideration liability

38,500


27,800

Other  liabilities 

899


92





Total liabilities 

119,616


83,115





Stockholders' equity:




Common stock, $0.001 par value:




100,000,000 shares authorized




68,795,987 and 61,130,740 shares issued and outstanding at December 31, 2012 and December 31, 2011

69


61

Additional paid-in capital 

220,489


198,565

Accumulated deficit 

(110,451)


(72,443)





Total stockholders' equity

110,107


126,183





Total liabilities and stockholders' equity

$229,723


$209,298

 

 

 

SOURCE Solta Medical, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

@ThingsExpo Stories
The Industrial Internet revolution is now underway, enabled by connected machines and billions of devices that communicate and collaborate. The massive amounts of Big Data requiring real-time analysis is flooding legacy IT systems and giving way to cloud environments that can handle the unpredictable workloads. Yet many barriers remain until we can fully realize the opportunities and benefits from the convergence of machines and devices with Big Data and the cloud, including interoperability, data security and privacy.
IoT is still a vague buzzword for many people. In his session at @ThingsExpo, Mike Kavis, Vice President & Principal Cloud Architect at Cloud Technology Partners, discussed the business value of IoT that goes far beyond the general public's perception that IoT is all about wearables and home consumer services. He also discussed how IoT is perceived by investors and how venture capitalist access this space. Other topics discussed were barriers to success, what is new, what is old, and what the future may hold. Mike Kavis is Vice President & Principal Cloud Architect at Cloud Technology Pa...
The Internet of Things (IoT) is rapidly in the process of breaking from its heretofore relatively obscure enterprise applications (such as plant floor control and supply chain management) and going mainstream into the consumer space. More and more creative folks are interconnecting everyday products such as household items, mobile devices, appliances and cars, and unleashing new and imaginative scenarios. We are seeing a lot of excitement around applications in home automation, personal fitness, and in-car entertainment and this excitement will bleed into other areas. On the commercial side, m...
SYS-CON Events announced today that CodeFutures, a leading supplier of database performance tools, has been named a “Sponsor” of SYS-CON's 16th International Cloud Expo®, which will take place on June 9–11, 2015, at the Javits Center in New York, NY. CodeFutures is an independent software vendor focused on providing tools that deliver database performance tools that increase productivity during database development and increase database performance and scalability during production.
Dale Kim is the Director of Industry Solutions at MapR. His background includes a variety of technical and management roles at information technology companies. While his experience includes work with relational databases, much of his career pertains to non-relational data in the areas of search, content management, and NoSQL, and includes senior roles in technical marketing, sales engineering, and support engineering. Dale holds an MBA from Santa Clara University, and a BA in Computer Science from the University of California, Berkeley.
The Internet of Things (IoT) promises to evolve the way the world does business; however, understanding how to apply it to your company can be a mystery. Most people struggle with understanding the potential business uses or tend to get caught up in the technology, resulting in solutions that fail to meet even minimum business goals. In his session at @ThingsExpo, Jesse Shiah, CEO / President / Co-Founder of AgilePoint Inc., showed what is needed to leverage the IoT to transform your business. He discussed opportunities and challenges ahead for the IoT from a market and technical point of vie...
The 3rd International Internet of @ThingsExpo, co-located with the 16th International Cloud Expo - to be held June 9-11, 2015, at the Javits Center in New York City, NY - announces that its Call for Papers is now open. The Internet of Things (IoT) is the biggest idea since the creation of the Worldwide Web more than 20 years ago.
Things are being built upon cloud foundations to transform organizations. This CEO Power Panel at 15th Cloud Expo, moderated by Roger Strukhoff, Cloud Expo and @ThingsExpo conference chair, addressed the big issues involving these technologies and, more important, the results they will achieve. Rodney Rogers, chairman and CEO of Virtustream; Brendan O'Brien, co-founder of Aria Systems, Bart Copeland, president and CEO of ActiveState Software; Jim Cowie, chief scientist at Dyn; Dave Wagstaff, VP and chief architect at BSQUARE Corporation; Seth Proctor, CTO of NuoDB, Inc.; and Andris Gailitis, C...
"People are a lot more knowledgeable about APIs now. There are two types of people who work with APIs - IT people who want to use APIs for something internal and the product managers who want to do something outside APIs for people to connect to them," explained Roberto Medrano, Executive Vice President at SOA Software, in this SYS-CON.tv interview at Cloud Expo, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
Performance is the intersection of power, agility, control, and choice. If you value performance, and more specifically consistent performance, you need to look beyond simple virtualized compute. Many factors need to be considered to create a truly performant environment. In his General Session at 15th Cloud Expo, Harold Hannon, Sr. Software Architect at SoftLayer, discussed how to take advantage of a multitude of compute options and platform features to make cloud the cornerstone of your online presence.
SYS-CON Media announced that Splunk, a provider of the leading software platform for real-time Operational Intelligence, has launched an ad campaign on Big Data Journal. Splunk software and cloud services enable organizations to search, monitor, analyze and visualize machine-generated big data coming from websites, applications, servers, networks, sensors and mobile devices. The ads focus on delivering ROI - how improved uptime delivered $6M in annual ROI, improving customer operations by mining large volumes of unstructured data, and how data tracking delivers uptime when it matters most.
In this Women in Technology Power Panel at 15th Cloud Expo, moderated by Anne Plese, Senior Consultant, Cloud Product Marketing at Verizon Enterprise, Esmeralda Swartz, CMO at MetraTech; Evelyn de Souza, Data Privacy and Compliance Strategy Leader at Cisco Systems; Seema Jethani, Director of Product Management at Basho Technologies; Victoria Livschitz, CEO of Qubell Inc.; Anne Hungate, Senior Director of Software Quality at DIRECTV, discussed what path they took to find their spot within the technology industry and how do they see opportunities for other women in their area of expertise.
DevOps Summit 2015 New York, co-located with the 16th International Cloud Expo - to be held June 9-11, 2015, at the Javits Center in New York City, NY - announces that it is now accepting Keynote Proposals. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long development cycles that produce software that is obsolete at launch. DevOps may be disruptive, but it is essential.
Almost everyone sees the potential of Internet of Things but how can businesses truly unlock that potential. The key will be in the ability to discover business insight in the midst of an ocean of Big Data generated from billions of embedded devices via Systems of Discover. Businesses will also need to ensure that they can sustain that insight by leveraging the cloud for global reach, scale and elasticity.
SYS-CON Media announced that Cisco, a worldwide leader in IT that helps companies seize the opportunities of tomorrow, has launched a new ad campaign in Cloud Computing Journal. The ad campaign, a webcast titled 'Is Your Data Center Ready for the Application Economy?', focuses on the latest data center networking technologies, including SDN or ACI, and how customers are using SDN and ACI in their organizations to achieve business agility. The Cisco webcast is available on-demand.
"BSQUARE is in the business of selling software solutions for smart connected devices. It's obvious that IoT has moved from being a technology to being a fundamental part of business, and in the last 18 months people have said let's figure out how to do it and let's put some focus on it, " explained Dave Wagstaff, VP & Chief Architect, at BSQUARE Corporation, in this SYS-CON.tv interview at @ThingsExpo, held Nov 4-6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
Advanced Persistent Threats (APTs) are increasing at an unprecedented rate. The threat landscape of today is drastically different than just a few years ago. Attacks are much more organized and sophisticated. They are harder to detect and even harder to anticipate. In the foreseeable future it's going to get a whole lot harder. Everything you know today will change. Keeping up with this changing landscape is already a daunting task. Your organization needs to use the latest tools, methods and expertise to guard against those threats. But will that be enough? In the foreseeable future attacks w...
As enterprises move to all-IP networks and cloud-based applications, communications service providers (CSPs) – facing increased competition from over-the-top providers delivering content via the Internet and independently of CSPs – must be able to offer seamless cloud-based communication and collaboration solutions that can scale for small, midsize, and large enterprises, as well as public sector organizations, in order to keep and grow market share. The latest version of Oracle Communications Unified Communications Suite gives CSPs the capability to do just that. In addition, its integration ...
Building low-cost wearable devices can enhance the quality of our lives. In his session at Internet of @ThingsExpo, Sai Yamanoor, Embedded Software Engineer at Altschool, provided an example of putting together a small keychain within a $50 budget that educates the user about the air quality in their surroundings. He also provided examples such as building a wearable device that provides transit or recreational information. He then reviewed the resources available to build wearable devices at home including open source hardware, the raw materials required and the options available to power s...
“The age of the Internet of Things is upon us,” stated Thomas Svensson, senior vice-president and general manager EMEA, ThingWorx, “and working with forward-thinking companies, such as Elisa, enables us to deploy our leading technology so that customers can profit from complete, end-to-end solutions.” ThingWorx, a PTC® (Nasdaq: PTC) business and Internet of Things (IoT) platform provider, announced on Monday that Elisa, Finnish provider of mobile and fixed broadband subscriptions, will deploy ThingWorx® platform technology to enable a new Elisa IoT service in Finland and Estonia.